These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34558384)

  • 1. Predictive value of vascular endothelial growth factor and placenta growth factor for placenta accreta spectrum.
    Faraji A; Akbarzadeh-Jahromi M; Bahrami S; Gharamani S; Raeisi Shahraki H; Kasraeian M; Vafaei H; Zare M; Asadi N
    J Obstet Gynaecol; 2022 Jul; 42(5):900-905. PubMed ID: 34558384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio.
    Zhang F; Gu M; Chen P; Wan S; Zhou Q; Lu Y; Li L
    Placenta; 2022 Jun; 124():48-54. PubMed ID: 35635854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of maternal serum VEGF, TNF-alpha, IL-4, and IL-10 levels in differentiating placenta accreta spectrum from isolated placenta previa.
    Farisoğullari N; Tanaçan A; Sakcak B; Denizli R; Baştemur AG; Başaran E; Kara Ö; Yazihan N; Şahin D
    Cytokine; 2024 Apr; 176():156513. PubMed ID: 38262117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of serum levels and placental bed tissue expression of IGF-1, bFGF, and PLGF in patients with placenta previa complicated with placenta accreta spectrum disorders.
    Arakaza A; Liu X; Zhu J; Zou L
    J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2305264. PubMed ID: 38247274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical value of serum VEGF and sFlt-1 in pernicious placenta previa.
    Wang N; Shi D; Li N; Qi H
    Ann Med; 2021 Dec; 53(1):2041-2049. PubMed ID: 34927512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The correlation between serum levels and placental tissue expression of PLGF and sFLT-1 and the FIGO grading of the placenta accreta spectrum disorders.
    Alessandrini L; Aryananda R; Ariani G; Agustina B; Akbar MIA; Dachlan EG; Dekker G; Ernawati E
    J Matern Fetal Neonatal Med; 2023 Dec; 36(1):2183744. PubMed ID: 36859823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum angiogenic profile in abnormal placentation.
    Biberoglu E; Kirbas A; Daglar K; Biberoglu K; Timur H; Demirtas C; Karabulut E; Danisman N
    J Matern Fetal Neonatal Med; 2016 Oct; 29(19):3193-7. PubMed ID: 26863111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between placenta accreta spectrum and third-trimester serum levels of vascular endothelial growth factor, placental growth factor, and soluble Fms-like tyrosine kinase-1: A meta-analysis.
    Alzoubi O; Maaita W; Madain Z; Alzoubi M; Sweis JJG; Arar AR; Sweis NWG
    J Obstet Gynaecol Res; 2022 Sep; 48(9):2363-2376. PubMed ID: 35726123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast.
    Wehrum MJ; Buhimschi IA; Salafia C; Thung S; Bahtiyar MO; Werner EF; Campbell KH; Laky C; Sfakianaki AK; Zhao G; Funai EF; Buhimschi CS
    Am J Obstet Gynecol; 2011 May; 204(5):411.e1-411.e11. PubMed ID: 21316642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening of placenta accreta spectrum disorder using maternal serum biomarkers and clinical indicators: a case-control study.
    Zhou J; Yang S; Xu X; Xu X; Wang X; Ye A; Chen Y; He F; Yu B
    BMC Pregnancy Childbirth; 2023 Jul; 23(1):508. PubMed ID: 37434137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologically diagnosed placenta accreta spectrum without placenta previa: a systematic review and meta-analysis.
    Sugai S; Yamawaki K; Sekizuka T; Haino K; Yoshihara K; Nishijima K
    Am J Obstet Gynecol MFM; 2023 Aug; 5(8):101027. PubMed ID: 37211089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Angiogenic and Anti-angiogenic Markers in Pregnant Women with Placenta Percreta.
    Uyanıkoğlu H; İncebıyık A; Turp AB; Çakmak G; Sak S; Hilali NG
    Balkan Med J; 2018 Jan; 35(1):55-60. PubMed ID: 28903888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective evaluation of impact of post-Cesarean section uterine scarring in perinatal diagnosis of placenta accreta spectrum disorder.
    Hussein AM; Elbarmelgy RA; Elbarmelgy RM; Thabet MM; Jauniaux E
    Ultrasound Obstet Gynecol; 2022 Apr; 59(4):474-482. PubMed ID: 34225385
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of fetal fibronectin and plasminogen activator inhibitor 1 biomarkers in antenatal prediction of placenta accreta spectrum.
    Okmen F; Ekici H; Koca E; Sucu V; Ogur M; Narin R
    J Obstet Gynaecol; 2022 Aug; 42(6):2008-2012. PubMed ID: 35653773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of abnormal placentation on maternal serum fetal fraction of cell-free DNA.
    Rodriguez M; Smith EL; Silva LM; Gultekin-Elbir EE; Tetla R; Genc MR
    J Perinat Med; 2023 Jan; 51(1):97-101. PubMed ID: 36383690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Association between Placenta Accreta Spectrum Severity and Incidence of Small for Gestational Age Neonates.
    Detlefs SE; Carusi DA; Modest AM; Einerson BD; Lyell D; Grace MR; Shrivastava VK; Khandelwal M; Salmanian B; Shainker SA; Fox KA; Subramaniam A; Crosland A; Duryea EL; Shamshirsaz AA; Shrestha K; Belfort MA; Silver RM; Clark SL; Shamshirsaz AA
    Am J Perinatol; 2023 Jan; 40(1):9-14. PubMed ID: 36096136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Placenta Accreta Spectrum Without Placenta Previa.
    Carusi DA; Fox KA; Lyell DJ; Perlman NC; Aalipour S; Einerson BD; Belfort MA; Silver RM; Shamshirsaz AA
    Obstet Gynecol; 2020 Sep; 136(3):458-465. PubMed ID: 32769646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrhagic morbidity in placenta accreta spectrum with and without placenta previa.
    Mulla BM; Weatherford R; Redhunt AM; Modest AM; Hacker MR; Hecht JL; Spiel MH; Shainker SA
    Arch Gynecol Obstet; 2019 Dec; 300(6):1601-1606. PubMed ID: 31691015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal and fetal outcome in placenta accreta spectrum (PAS) associated with placenta previa: a retrospective analysis from a tertiary center.
    Varlas VN; Bors RG; Birsanu S; Maxim B; Clotea E; Mihailov M
    J Med Life; 2021; 14(3):367-375. PubMed ID: 34377203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of serum placental growth factor levels in preeclamptic and normotensive pregnant women in Lagos, Nigeria: a worthwhile screening tool?
    Oluwole AA; Onakoya AA; Okunade KS; Babah OA; Akinajo O
    J Obstet Gynaecol; 2022 Aug; 42(6):1944-1949. PubMed ID: 35603727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.